Genus plc, together with its subsidiaries, engages in the application of quantitative genetics and biotechnology for animal breeding in the porcine and bovine sectors. It operates through three segments: Genus PIC, Genus ABS, and Research and Development. The company sells sows, boars, and semen under the PIC name to breed pigs with various characteristics for pork production. It also sells bull semen and embryos that are delivered through artificial insemination to breed diary and beef cattle with various characteristics for milk and beef production under the ABS name, as well as provides various in vitro fertilization services under the IVB name. The company serves pork, beef, and dairy farmers in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:GNS
CUSIPN/A
Phone+44-1256-347100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins4.44%
Return on Equity4.92%
Return on Assets2.69%
Miscellaneous
EmployeesN/A
Outstanding Shares61,530,000
Market Cap£1.43 billion
Genus (LON:GNS) Frequently Asked Questions
What is Genus' stock symbol?
Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS."
How often does Genus pay dividends? What is the dividend yield for Genus?
Genus announced a dividend on Thursday, September 6th. Investors of record on Thursday, November 15th will be paid a dividend of GBX 17.90 per share on Friday, November 30th. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend is Thursday, November 15th. This is an increase from Genus's previous dividend of $8.10. The official announcement can be viewed at this link. View Genus' Dividend History.
What price target have analysts set for GNS?
5 brokerages have issued twelve-month price objectives for Genus' shares. Their predictions range from GBX 1,800 to GBX 2,600. On average, they anticipate Genus' stock price to reach GBX 2,365 in the next twelve months. This suggests that the stock has a possible downside of 6.9%. View Analyst Price Targets for Genus.
What is the consensus analysts' recommendation for Genus?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genus.
Who are some of Genus' key competitors?
Some companies that are related to Genus include ABLYNX NV/ADR (ABLX), MorphoSys (MPSYY), BTG (BTG), Abcam (ABC), MorphoSys (MOR), Almirall (LBTSF), Sosei Group (SOLTF), Sirtex Medical (SRX), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF) and Emerald Health Therapeutics (EMH).
Who are Genus' key executives?
Genus' management team includes the folowing people:
- Mr. Karim Bitar, Chief Exec. Officer and Exec. Director (Age 53)
- Mr. Stephen Wilson, Group Fin. Director & Exec. Director (Age 58)
- Dr. Jonathan Lightner Ph.D., Chief of R&D and Scientific Officer
- Mr. Dan Hartley, Group Gen. Counsel & Company Sec.
- Ms. Angelle R. Rosata SPHR, Group HR Director
Has Genus been receiving favorable news coverage?
Media stories about GNS stock have trended somewhat positive recently, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genus earned a daily sentiment score of 0.18 on Accern's scale. They also gave news stories about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Genus.
How do I buy shares of Genus?
Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Genus' stock price today?
One share of GNS stock can currently be purchased for approximately GBX 2,540.
How big of a company is Genus?
Genus has a market capitalization of £1.43 billion.
How can I contact Genus?
Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100.
MarketBeat Community Rating for Genus (LON GNS)
MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote "Outperform" if you believe GNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
